*Int.J.Curr.Res.Aca.Rev.2024; 12(1): 1-4*

EXCELLENT PUBLISHERS

# International Journal of Current Research and Academic Review

**ISSN: 2347-3215 (Online) Volume 12 Number 1 (January-2024)**

Journal homepage: http://www.ijcrar.com

**doi:** https://doi.org/10.20546/ijcrar.2024.1201.001

# Screening and Therapeutic Management of Chronic Hepatitis in a German Shepherd

**Pavan Goyal***

*Department of Veterinary Medicine, Apollo College of Veterinary Medicine, Jaipur, India*

**Corresponding author*

## Abstract

Three-year-old German Shepherd dog with a history and clinical indications of fever (106 °F), congested mucous membrane, anorexia, ascites, and black feces for four days was brought to the Veterinary Medicine unit of the Teaching Veterinary Clinical Complex of Apollo College of Veterinary Medicine, Jaipur. The current case was identified as having chronic hepatitis and is being treated as such based on hematobiochemical and ultrasonographic data. The dog's condition significantly improved after five days of medication, and all parameters were within normal limits.

## Article Info

*Received: 27 November 2023*
*Accepted: 31 December 2023*
*Available Online: 20 January 2024*

## Keywords

D-penicillamine, prednisolone and chronic hepatitis.

## Introduction

Fibrillary extracellular matrix (ECM) components gradually accumulate in the liver as a result of hepatic fibrosis (Gressner *et al.,* 2008; Bircher, 1999 and Friedman, 2007). Excess ECM accumulates as a result of an imbalance between ECM deposition and clearance during the wound healing response to chronic damage and inflammation (Ramachandran and Iredale, 2012).

Chronic hepatitis, which is histologically characterized by hepatocyte necrosis or apoptosis, inflammation, mononuclear cell infiltration, and fibrosis, is the most frequent cause of hepatic fibrosis in dogs. Particularly in cases of idiopathic chronic hepatitis, the fibrosis initially appears in the liver's periportal zones and frequently co-localizes with necrosis (Cullen, 2009). Van den Ingh *et al.,* (2017) reported that portal-portal or portal-central bridging fibrosis may occur with more advanced fibrosis, eventually leading to the creation of distinct nodules. Centrilobular zones are typically where copper accumulates first when it is the main cause of liver illness. Labrador retrievers with chronic hepatitis linked to copper were shown to have cilioblastular to bridging fibrosis (Smedley *et al.,* 2009). Granulomatous hepatitis is an uncommon form of chronic hepatitis in dogs (Poldervaart *et al.,* 2009). It can be caused by lymphoma and histiocytosis, as well as infectious diseases like leishmaniasis (Rallis *et al.,* 2005), schistosomiasis (Rodriguez *et al.,* 2014), histoplasmosis (Chapman *et al.,* 1993), *Angiostrongylus vasorum* infection (Cook *et al.,* 2015), and *Angiostrongylus vasorum* infection (Rallis *et al.,* 2005).

Prolonged inflammation causes fibrosis in cases of chronic hepatitis, regardless of the underlying cause. Fibrosis surrounding biliary ducts may arise from occlusion of the extrahepatic bile duct, most likely due to the growth of portal myofibroblasts. Dogs' pancreatic or biliary tumors, inflammation, or cholelithiasis are among the conditions that can cause obstruction of the extrahepatic bile duct (Rothuizen, 2008). Dog cholangitis

is less well-documented than cat cholangitis (Tamborini *et al.,* 2016), and biliary fibrosis may result from chronic cholangitis.

Portal-portal bridging fibrosis and biliary cirrhosis can develop from biliary fibrosis (Cullen, 2015). Destructive cholangitis is characterized by loss of bile ducts with concomitant inflammation, may lead to fibrosis of bile ducts (Cullen, 2015; Osumi *et al.,* 2011).

This rare condition has been linked to idiosyncratic medication reactions (Gabriel *et al.,* 2006). Increased CVP and passive venous hepatic congestion are caused by right-sided heart failure or blockage of the cranial vena cava. Ischemia and necrosis transpire as a result of decreased liver perfusion (Li *et al.,* 2012). Centrilobular fibrosis can result from this over time. Following the use of a poison, a similar pattern may emerge (Cullen, 2015). Regression of fibrosis may occur from blocking mediators of collagen deposition or increasing mediators of extracellular matrix breakdown, as fibrosis is now understood to be a continuous remodeling process in which either net collagen deposition or resolution occurs (Younis *et al.,* 2016).

## Materials and Methods

A three-year-old German shepherd dog with a history and clinical indications of fever (106 °F), congested mucous membrane, anorexia, ascites, and black feces for four days was brought to the Veterinary Medicine unit of the Teaching Veterinary Clinical Complex of Apollo College of Veterinary Medicine, Jaipur. Following the clinical evaluation, serum and blood samples were taken for hemato-biochemical analysis, and ultrasonography was also carried out at the same time.

## Results and Discussion

Hematological examination showed that while other values were within the normal range, hemoglobin concentration, total erythrocyte count, lymphocyte count, and neutrophil count were all reduced (Table 1). Serum total protein, serum albumin, and A:G ratio were found to be lower in the serum biochemical test, but total serum bilirubin, direct bilirubin, AST, and ALT were found to be higher (Table 2). The results of the ultrasonographic examination showed a partially enlarged gall bladder, partially distended hepatic lobes that appeared to have shrunken, complete loss of architectural details in the parenchyma, hyperechoic echogenicity of the liver to spleen in certain areas and lobes, and an abundance of clear, free abdominal fluid. The liver's margins were clearly visible but noticeably rough, rounded, and uneven. Based on the results of this investigation, the patient's condition was determined to be chronic hepatitis. Treatment included the following: injection of Amoxirum forte (20 mg/kg b.wt intravenously bid), oral administration of Hepasafe Plus syrup (5 ml), injection of Neuroxin-M (4 ml intravenous daily), and injection of furosemide (2 mg/kg b.wt intramuscularly). Following a five-day course of treatment, the condition of the patient showed a noticeable improvement, with all metrics falling within the normal range.

Chelation with D-penicillamine reduces hepatic fibrosis. It might have to do with less collagen being formed. One kind of tissue molecule that develops as scar tissue as a result of inflammation is collagen. According to Dirksen and Fieten (2017), penicillamine binds copper, iron, mercury, lead, and cystine, which are subsequently eliminated in the urine. In the cytoplasm, glucocorticoids bind to glucocorticoid receptors.

**Table.1** Hematology

| Parameter | Value | Normal Range |
|---|---|---|
| **Hb (g/dL)** | 8.7 | 11.9-18.9 |
| **T.E.C. (Million/mm$^3$)** | 2.05 | 4.95-7.87 |
| **T.L.C. (10$^3$/mm$^3$)** | 12.5 | 5.0-14.1 |
| **D.L.C.** | | |
| **Neutrophils %** | 78 | 58-85 |
| **Lymphocytes %** | 17 | 08-21 |
| **Monocytes %** | 05 | 02-10 |
| **Hemoprotozoa** | Negative | - |

**Table.2** Serum biochemistry

| Parameter | Value | Normal range |
|---|---|---|
| **Serum Bilirubin (mg %)** | | |
| **Total** | 1.7 | 0.1-1.0 |
| **Direct** | 1.3 | 0.1-0.5 |
| **Indirect** | 0.4 | 0.1-0.5 |
| **AST (IU/L)** | 87 | 08-37 |
| **ALT (IU/L)** | 123 | 10-88 |
| **ALKP (IU/L)** | 460 | 037-147 |
| **Serum Proteins (g/dL)** | | |
| **Total Protein** | 5.5 | 6.0-8.2 |
| **Albumin** | 2.3 | 3.5-5.2 |
| **Globulin** | 3.2 | 2.6-3.8 |
| **A:G** | 0.72 | 1.5-2.1 |

After translocating to the nucleus, these complexes activate glucocorticoid response elements and trigger the transcription of genes that code for immunomodulatory and anti-inflammatory proteins, such as IL-10 (Barnes, 1998). Nuclear factor-kappa B and activator protein-1 regulate transcription of inflammatory genes. These transcription factors' effects are inhibited by glucocorticoids (Kagoshima *et al.,* 2003 and Adcock *et al.,* 2004). Longer median survival periods were linked to prednisolone treatment (Strombeck *et al.,* 1988).

## Data Availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

## Declarations

**Ethical Approval** Not applicable.

**Consent to Participate** Not applicable.

**Consent to Publish** Not applicable.

**Conflict of Interest** The authors declare no competing interests.

## References


Adcock, I. M.; Ito, K. and Barnes, P. J. (2004). Glucocorticoids: Effects on gene transcription. *Proc Am Thorac Soc*, 1: 247–254.

Barnes, P. J. (1998). Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. *Clin Sci*, 94: 557–572.

Bircher, J. (1999). Oxford Textbook of Clinical Hepatology, 2nd ed. Oxford; NY: Oxford University Press.

Chapman, B. L.; Hendrick, M. J. and Washabau, R. J. (1993). Granulomatous hepatitis in dogs: Nine cases (1987–1990). *J Am Vet Med A*, 203: 680–684.

Cook, S.; Priestnall, S. L.; Blake, D. *et al.,* (2015). *Angiostrongylus vasorum* causing severe granulomatous hepatitis with concurrent multiple acquired PSS. *J Am Anim Hosp Assoc,*51: 320–324.

Cullen, J. (2015). Liver and Biliary System. In: Maxie G, ed. Jubb, Kennedy & Palmer's Pathology of Domestic Animals, 6th ed. Philadelphia, PA: Saunders Elsevier: 258–352.

Cullen, J. M. (2009). Summary of the World Small Animal Veterinary Association standardization committee guide to classification of liver disease in dogs and cats. *Vet Clin North Am Small Anim Pract*, 39: 395–418.

Dirksen, K. and Fieten, H. (2017). Canine copper-associated hepatitis. *Vet Clin North Am Small Anim Pract*, 47: 631–644.

Friedman, S. L. (2007). Hepatic fibrosis. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Schiff's Diseases of the Liver, 10th ed. Philadelphia: Lippincott Williams & Wilkins:297–315.

Gabriel, A.; van den Ingh, T. S.; Clercx, C. *et al.,* (2006). Suspected drug-induced destructive cholangitis in a young dog. *J Small Anim Pract,* 47: 344–348.

Gressner, O. A.; Rizk, M. S.; Kovalenko, E. *et al.,* (2008). Changing the pathogenetic roadmap of

liver fibrosis? Where did it start; where will it go? *J Gastroenterol Hepatol*, 23: 1024–1035.

Kagoshima, M.; Ito, K.; Cosio, B. *et al.,* (2003). Glucocorticoid suppression of nuclear factor-kappa B: A role for histone modifications. *Biochem Soc Trans*, 31: 60–65.

Li, P.; Robertson, T. A.; Zhang, Q. *et al.,* (2012). Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. *Pharm Res,* 29: 1658–1669.

Osumi, T.; Ohno, K.; Kanemoto, H. *et al.,* (2011). A case of recovery from canine destructive cholangitis in a Miniature Dachshund. *J Vet Med Sci,* 73: 937–939.

Poldervaart, J. H.; Favier, R. P.; Penning, L. C. *et al.,* (2009). Primary hepatitis in dogs: A retrospective review (2002–2006). *J Vet Intern Med*, 23: 72–80

Rallis, T.; Day, M. J.; Saridomichelakis, M. N. *et al.,* (2005). Chronic hepatitis associated with canine leishmaniosis (*Leishmania infantum*): A clinicopathological study of 26 cases. *J Comp Pathol*, 132: 145–152.

Ramachandran, P. and Iredale, J. P. (2012). Liver fibrosis: A bidirectional model of fibrogenesis and resolution. *QJM*, 105: 813–817.

Rodriguez, J. Y.; Lewis, B. C. and Snowden, K. F. (2014). Distribution and characterization of *Heterobilharzia americana* in dogs in Texas. *Vet Parasitol*, 203: 35–42.

Rothuizen, J. (2008). Liver diseases of the dog. In: Steiner JM, ed. Small Animal Gastroenterology. Hannover, Germany: Schluetersche Verlagsgesellschaft:241–281.

Smedley, R.; Mullaney, T. and Rumbeiha, W. (2009). Copper-associated hepatitis in Labrador retrievers. *Vet Pathol*, 46: 484–490.

Strombeck, D. R.; Miller, L. M. and Harrold, D. (1988). Effects of corticosteroid treatment on survival time in dogs with chronic hepatitis: 151 cases (1977-1985). *J Am Vet Med Assoc*, 193: 1109–1113.

Tamborini, A.; Jahns, H.; McAllister, H. *et al.,* (2016). Bacterial cholangitis, cholecystitis, or both in dogs. *J Vet Intern Med*, 30: 1046–1055.

van den Ingh, T. S.; Van Winkle, T.; Cullen, J. M. *et al.,* (2017). Morphological classification of parenchymal disorders of the canine and feline liver: hepatocellular death, hepatitis, and cirrhosis-2 (updated version). In: World Small Animal Veterinary Association Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Diseases. *Society of Comparative Hepatology*. Available at: http:// www. Vetvisuals.com/lms/moodle/mod/ book/view. php?id=1001& chapter id=52859.

Younis, N.; Shaheen, M. A. and Abdallah, M. H. (2016). Silymarin-loaded Eudragit RS100 nanoparticles improved the ability of silymarin to resolve hepatic fibrosis in bile duct ligated rats. *Biomed Pharmacother*, 81: 93–103.

**How to cite this article:**

Pavan Goyal. 2024. Screening and Therapeutic Management of Chronic Hepatitis in a German Shepherd. *Int.J.Curr.Res.Aca.Rev.* 12(1), 1-4. doi: https://doi.org/10.20546/ijcrar.2024.1201.001